Erratum: Notch3 overexpression associates with poor prognosis in human non-small-cell lung cancer (Medical Oncology (2013) 30 (595) DOI: 10.1007/s12032-013-0595-7);Notch3 overexpression associates with poor prognosis in human non-small-cell lung cancer

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Ye, Yuan Zi ^a   Zhang, Zhi Hong ^a   Fan, Xiao Yun ^a   Xu, Xiao Lan ^a   Chen, Mei Li ^a   Chang, Bo Wen ^a   Zhang, Yan Bei ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Immunohistochemistry; Notch3; Prognosis; Western blot

Indexed keywords

NOTCH3 RECEPTOR; NOTCH RECEPTOR; NOTCH3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; WESTERN BLOTTING; BIOSYNTHESIS; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS;

BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, NOTCH;

EID: 84876829829     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0716-3     Document Type: Erratum

References (25)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60(5):277-300.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012;62(1):10-29.
3. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review 1975-2009 (vintage: populations). Bethesda: National Cancer Institute; 2009.
4. Sandler A, Gray R, Perry M, et al. Paclitaxel-carboplatin alone or with bevacizumab in non-small cell lung cancer. NEJM. 2006;355(24):2542-50.
5. Lee SY, Kim MJ, Jin G, et al. Choi somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol. 2010;5(11):1734-40.
6. Casás-Selves M, Kim J, Zhang Z, et al. Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res. 2012;72(16):4154-64.
7. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389-95.
8. Shawber CJ, Kitajewski J. Notch function in the vasculature: insights from zebrafish, mouse and man. BioEssays. 2004;26:225-34.
9. Gridley T. Notch signaling during vascular development. Proc Natl Acad Sci USA. 2001;98:5377-8.
10. Collins BJ, Kleeberger W, Ball DW. Notch in lung development and lung cancer. Semin Cancer Biol. 2004;14:357-64.
11. Lin L, Mernaugh R, Yi F, et al. Targeting specific regions of the Notch3 ligand-binding domain induces apoptosis and inhibits tumor growth in lung cancer. Cancer Res. 2010;70:632-8.
12. Westhoff B, Colaluca IN, D'Ario G, et al. Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci USA. 2009;106:22293-8.
13. Baumgart A, Seidl S, Vlachou P, et al. ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer. Cancer Res. 2010;70:5368-78.
14. Park JT, Chen X, Trope CG, et al. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol. 2010;177:1087-94.
15. Rahman MT, Nakayama K, Rahman M, et al. Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer. Am J Clin Pathol. 2012;138(4):535-44.
16. Jonusiene V, Sasnauskiene A, Lachej N, et al. Down-regulated expression of Notch signaling molecules in human endometrial cancer. Med Oncol. 2013;30(1):438.
17. Yao J, Qian C. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway. Med Oncol. 2010;27(3):1017-22.
18. Mann CD, Bastianpillai C, Neal CP, et al. Notch3 and HEY-1 as prognostic biomarkers in pancreatic adenocarcinoma. PLoS ONE. 2012;7(12):e51119.
19. Kang H, An HJ, Song JY, et al. Notch3 and Jagged2 contribute to gastric cancer development and to glandular differentiation associated with MUC2 and MUC5AC expression. Histopathology. 2012;61:576-86.
20. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136(1):260-71.
21. Mitsuhashi Y, Horiuchi A, Miyamoto T, et al. Prognostic significance of Notch signalling molecules and their involvement in the invasiveness of endometrial carcinoma cells. Histopathology. 2012;60(5):826-37.
22. Yeasmin S, Nakayama K, Rahman MT, et al. Expression of nuclear Notch3 in cervical squamous cell carcinomas and its association with adverse clinical outcomes. Gynecol Oncol. 2010;117:409-16.
23. Ma D, Dong X, Zang S, et al. Aberrant expression and clinical correlation of Notch signaling molecules in breast cancer of Chinese population. Asia Pac J Clin Oncol. 2011;7(4):385-91.
24. Shah MM, Zerlin M, Li BY, et al. The role of notch and gamma-secretase inhibition in an ovarian cancer model. Anticancer Res. 2013;33(3):801-8.
25. Chen X, Thiaville MM, Chen L, et al. Defining NOTCH3 target genes in ovarian cancer. Cancer Res. 2012;72(9):2294-303.